6CM
AEON icon

683 Capital Management’s AEON Biopharma AEON Stock Holding History

683 Capital Management’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-139
Closed -$101K – 299
2022
Q4 		$101K Hold
139
– – 0.01% 234
2022
Q3 		$98K Hold
139
– – 0.01% 157
2022
Q2 		$98K Hold
139
– – 0.01% 190
2022
Q1 		$98K Hold
139
– – 0.01% 290
2021
Q4 		$98K Hold
139
– – ﹤0.01% 304
2021
Q3 		$97K Buy
+139
New +$97.1K ﹤0.01% 194

Other funds holding AEON

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
CCA
Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
GCWM
Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

683 Capital Management's AEON Position: Q1 2023 in Review

683 Capital Management sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 139 shares — an estimated $101K sold.

683 Capital Management first reported a position in AEON in Q3 2021 and held it in 6 quarters. The position peaked at $101K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

  • 683 Capital Management reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
  • 683 Capital Management sold 139 AEON Biopharma shares in Q1 2023, an estimated $101K.
  • 683 Capital Management first reported a position in AEON Biopharma in Q3 2021 and held it in 6 quarters.
  • 683 Capital Management's AEON Biopharma position peaked at $101K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.